DTIL News and Press, Precision BioSciences Inc. From 05/10/24

2024-05-10 12:45:24 ET More on Precision BioSciences Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration Precision BioSciences stock falls after pricing $40M securities offering Seeking Alpha’s Quant Rating on Precision BioSciences ...

Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, tod...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish f...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that its partner ...

2024-05-06 15:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Data to be presented will highlight latest preclinical safety data for PBGENE-HBV in preparation for regulatory filings in 2024 Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene ...

2024-04-26 21:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-17 10:24:12 ET Summary TG Therapeutics shares are down 60% from their 52-week high after rival MS therapy Ocrevus achieved non-inferiority as a subcutaneously injected therapy. Initial sales of TG Therapeutics' anti-CD20 MS treatment Briumvi were solid, generating $92 mill...

2024-04-16 16:59:57 ET More on Precision BioSciences Precision BioSciences stock falls after pricing $40M securities offering Precision BioSciences announces proposed public offering of common stock and warrants Seeking Alpha’s Quant Rating on Precision BioSci...

- Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insertion - Precision exercised option to regain control of programs and intends to bring collaboration programs back to develop independently or with new partners ...